Gelteq Limited Ordinary Shares
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GELS research report →
Price Chart
About the company
Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.
- CEO
- Nathan Jacob Givoni
- IPO
- 2024
- Employees
- 18
- HQ
- Clayton, VIC, AU
Get TickerSpark's AI analysis on GELS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.12M
- P/E
- -2.17
- PEG
- -0.02
- P/S
- 40.25
- P/B
- 0.57
- EV/EBITDA
- -4.20
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1986.04%
- Net Margin
- -2095.34%
- ROE
- -24.94%
- ROIC
- -18.33%
Latest fiscal year · YoY change
- Revenue
- $165.65K+0.0%
- Gross Profit
- $165.65K+0.0%
- Op Income
- $-5,495,527
- Net Income
- $-6,645,453-87.4%
- EPS
- $0.00+0.0%
- OCF Growth
- -415.8%
- FCF Growth
- -405.8%
- 52W High
- $2.02
- 52W Low
- $0.39
- 50D MA
- $0.67
- 200D MA
- $0.77
- Beta
- -0.43
- RSI (14)
- 46
- Avg Volume
- 3.68M
No earnings-call transcripts are available for GELS yet.
- Free Float
- 39.6%
- Shares Outstanding
- 9.18M
- Float Shares
- 3.64M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | WYNNE Paul Michael | other | 0 |
| Mar 18, 26 | Szewach Simon H | other | 0 |
| Jul 1, 26 | Szewach Simon H | other | 65,000 |
| Mar 18, 26 | Karp Bradley Glenn | other | 0 |
| Mar 18, 26 | Givoni Nathan J | other | 0 |
| Jul 1, 26 | Givoni Nathan J | other | 15,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GELS coverage
Recent articles, reports, and earnings notes.
No research on GELS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GELS report →Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs
globenewswire.com · Jun 17
Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications
globenewswire.com · Jun 12
Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications
globenewswire.com · Jun 12
Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion
globenewswire.com · Jun 4
Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway
globenewswire.com · May 20
Healthy Extracts Q1 2026 Net Revenue Up 73% to Record $1.6 Million, Driving Positive EBITDA
accessnewswire.com · May 14
Gelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue Growth
globenewswire.com · May 12
Healthy Extracts Reports 2025 Net Revenue Up 45% to Record $4.5 Million
accessnewswire.com · Apr 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.